Search Results Label

Seqirus has been on the front line of pandemic preparedness for more than a century. Learn more about our rapid vaccine production capabilities.

https://www.seqirus.com.au/expertise/influenza/pandemic-response-solutions

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.com.au/expertise

Seqirus is one of the largest influenza vaccine companies in the world, with state-of-the-art manufacturing facilities on three continents. Learn more.

https://www.seqirus.com.au/manufacturing/global-manufacturing-network

Seqirus, as a member of the CSL group, is bound by CSL's Code of Responsible Business Practice. Access our annual financial and diversity disclosures.

https://www.seqirus.com.au/our-company/corporate-responsibility/disclosures

Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.

https://www.seqirus.com.au/-/media/seqirus/pdfs/csl-statement-on-modern-slavery-2020.pdf

Seqirus Pty Ltd (Seqirus) and Gedeon Richter Plc (Richter) today announced the signing of an exclusive license agreement to commercialise a novel antipsychotic in Australia and New Zealand.

https://www.seqirus.com.au/news/seqirus-and-richter-sign-a-license-agreement-for-the-commercialisation-of-a-novel-treatment

RAPIVAB (peramivir injection) is a single-dose intravenous treatment for acute uncomplicated influenza, which was developed under contract with the US Government as part of pandemic preparedness efforts.

https://www.seqirus.com.au/-/media/seqirus-australia/news-docs/csl-acquires-exclusive-rights-to-influenza-treatment--news-release-170615.pdf

CSL Limited (ASX:CSL) today announced it has acquired exclusive rights to commercialise the influenza treatment, RAPIVAB®, from US-based company, BioCryst Pharmaceuticals Inc (NASDAQ: BCRX).

https://www.seqirus.com.au/news/csl-acquires-exclusive-rights-to-influenza-treatment

Seqirus, a CSL Company created in July 2015 from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis, is a transcontinental partner in pandemic preparedness and a major contributor to the prevention of control of influenza globally.

https://www.seqirus.com.au/-/media/seqirus-australia/news-docs/afluria-quad-2017-consumer-release--seqirus-newsroomfinal.pdf

A quadrivalent flu vaccine manufactured by Seqirus locally in Melbourne, Australia is available for the 2017 Australian flu season for adults aged 18 years and older.

https://www.seqirus.com.au/news/afluria-quad-a-four-strain-flu-vaccine-manufactured-in-australia-is-now-available